Press Releases

 

GW Pharmaceuticals Announces New Physician Reports of Epidiolex® Treatment Effect in Children and Young Adults with Treatment-Resistant Epilepsy

14 October 2014

- Physician reports show signals of efficacy and safety consistent with previously disclosed data, as well as maintenance of clinical effect beyond 12 weeks and high retention rate - - Data to be pre... more

GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Totaling Approximately $169.8 Million on the NASDAQ Global Market and Full Exercise of Underwriters' Option to Purchase Additional ADSs

25 June 2014

LONDON, UK, 25 June, 2014 -- GW Pharmaceuticals plc (Nasdaq: GWPH) (AIM: GWP) ("GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeu... more

GW Pharmaceuticals plc Announces Pricing of U.S. Public Offering of ADSs Totaling Approximately $148 Million on NASDAQ Global Market

18 June 2014

London, UK, 18 June 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics ... more

GW Pharmaceuticals Announces Physician Reports of Epidiolex® Treatment Effect in Children and Young Adults with Treatment-Resistant Epilepsy from Physician-Led Expanded Access Treatment Program

17 June 2014

London, UK; 17 June 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel ... more

Atlanta, Georgia, and London, UK 27 May 2014: A State of Georgia initiative making it possible to treat children with epilepsy with cannabidiol is moving forward.

27 May 2014

The state, GW Pharmaceuticals (NASDAQ: GWPH), and Georgia Regents University Augusta (GRU), announced today that they have entered into a Memorandum of Understanding to study GW’s investigational cann... more

GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2/3 Clinical Trial of Epidiolex® in the Treatment of Dravet Syndrome

7 May 2014

London, UK; 7 May 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing, and commercializing novel t... more

GW Pharmaceuticals plc Announces the Closing of its U.S. Follow-on Offering of American Depositary Shares (ADSs) on the Nasdaq Global Market and Full Exercise of Underwriters’ Option to Purchase Additional ADSs - Offering raises $101.1 million

14 January 2014

London, UK, January 14, 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeu... more